Johanna P van Gemert1,2, Inge A H van den Berk3, Esther J Nossent4, Leo M A Heunks5, Rene E Jonkers6, Alexander P Vlaar7, Peter I Bonta6. 1. Department of Intensive Care Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, The Netherlands. j.p.van.gemert@umcg.nl. 2. Department of Pulmonary Diseases, University Medical Center Groningen (UMCG), Hanzeplein 1, HP BB72, 9700 RB, Groningen, The Netherlands. j.p.van.gemert@umcg.nl. 3. Department of Radiology, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, The Netherlands. 4. Department of Respiratory Medicine, Amsterdam University Medical Center, Location VUMC, Vrije Universiteit, Amsterdam, The Netherlands. 5. Department of Intensive Care Medicine, Amsterdam University Medical Center, Location VUMC, Vrije Universiteit, Amsterdam, The Netherlands. 6. Department of Respiratory Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, The Netherlands. 7. Department of Intensive Care Medicine, Amsterdam University Medical Center, Location AMC, University of Amsterdam, Amsterdam, The Netherlands.
Abstract
BACKGROUND: Treatment for interstitial lung disease (ILD) patients with acute respiratory failure (ARF) is challenging, and literature to guide such treatment is scarce. The reported in-hospital mortality rates of ILD patients with ARF are high (62-66%). Cyclophosphamide is considered a second-line treatment in steroid-refractory ILD-associated ARF. The first aim of this study was to evaluate the in-hospital mortality in patients with ILD-associated ARF treated with cyclophosphamide. The second aim was to compare computed tomographic (CT) patterns and physiological and ventilator parameters between survivors and non-survivors. METHODS: Retrospective analysis of patients with ILD-associated ARF treated with cyclophosphamide between February 2016 and October 2017. Patients were categorized into three subgroups: connective tissue disease (CTD)-associated ILD, other ILD or vasculitis. In-hospital mortality was evaluated in the whole cohort and in these subgroups. Clinical response was determined using physiological and ventilator parameters: Sequential Organ Failure Assessment Score (SOFA), PaO2/FiO2 (P/F) ratio and dynamic compliance (Cdyn) before and after cyclophosphamide treatment. The following CT features were quantified: ground-glass opacification (GGO) proportion, reticulation proportion, overall extent of parenchymal disease and fibrosis coarseness score. RESULTS: Fifteen patients were included. The overall in-hospital mortality rate was 40%. In-hospital mortality rates for CTD-associated ILD, other ILD and vasculitis were 20, 57, and 33%, respectively. The GGO proportion (71% vs 45%) was higher in non-survivors. There were no significant differences in the SOFA score, P/F ratio or Cdyn between survivors and non-survivors. However, in survivors the P/F ratio increased from 129 to 220 mmHg and Cdyn from 75 to 92 mL/cmH2O 3 days after cyclophosphamide treatment. In non-survivors the P/F ratio hardly changed (113-114 mmHg) and Cdyn even decreased (27-20 mL/cmH2O). CONCLUSION: In this study, we found a mortality rate of 40% in patients treated with cyclophosphamide for ILD-associated ARF. Connective tissue disease-associated ILD and vasculitis were associated with a lower risk of death. In non-survivors, the CT GGO proportion was significantly higher. The P/F ratio and Cdyn in survivors increased after 3 days of cyclophosphamide treatment.
BACKGROUND: Treatment for interstitial lung disease (ILD) patients with acute respiratory failure (ARF) is challenging, and literature to guide such treatment is scarce. The reported in-hospital mortality rates of ILD patients with ARF are high (62-66%). Cyclophosphamide is considered a second-line treatment in steroid-refractory ILD-associated ARF. The first aim of this study was to evaluate the in-hospital mortality in patients with ILD-associated ARF treated with cyclophosphamide. The second aim was to compare computed tomographic (CT) patterns and physiological and ventilator parameters between survivors and non-survivors. METHODS: Retrospective analysis of patients with ILD-associated ARF treated with cyclophosphamide between February 2016 and October 2017. Patients were categorized into three subgroups: connective tissue disease (CTD)-associated ILD, other ILD or vasculitis. In-hospital mortality was evaluated in the whole cohort and in these subgroups. Clinical response was determined using physiological and ventilator parameters: Sequential Organ Failure Assessment Score (SOFA), PaO2/FiO2 (P/F) ratio and dynamic compliance (Cdyn) before and after cyclophosphamide treatment. The following CT features were quantified: ground-glass opacification (GGO) proportion, reticulation proportion, overall extent of parenchymal disease and fibrosis coarseness score. RESULTS: Fifteen patients were included. The overall in-hospital mortality rate was 40%. In-hospital mortality rates for CTD-associated ILD, other ILD and vasculitis were 20, 57, and 33%, respectively. The GGO proportion (71% vs 45%) was higher in non-survivors. There were no significant differences in the SOFA score, P/F ratio or Cdyn between survivors and non-survivors. However, in survivors the P/F ratio increased from 129 to 220 mmHg and Cdyn from 75 to 92 mL/cmH2O 3 days after cyclophosphamide treatment. In non-survivors the P/F ratio hardly changed (113-114 mmHg) and Cdyn even decreased (27-20 mL/cmH2O). CONCLUSION: In this study, we found a mortality rate of 40% in patients treated with cyclophosphamide for ILD-associated ARF. Connective tissue disease-associated ILD and vasculitis were associated with a lower risk of death. In non-survivors, the CT GGO proportion was significantly higher. The P/F ratio and Cdyn in survivors increased after 3 days of cyclophosphamide treatment.
Authors: B Bradley; H M Branley; J J Egan; M S Greaves; D M Hansell; N K Harrison; N Hirani; R Hubbard; F Lake; A B Millar; W A H Wallace; A U Wells; M K Whyte; M L Wilsher Journal: Thorax Date: 2008-09 Impact factor: 9.139
Authors: A Vial-Dupuy; O Sanchez; B Douvry; L Guetta; K Juvin; D Wermert; E Guérot; D Israël-Biet Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2013-08-01 Impact factor: 0.670
Authors: Whitney D Gannon; David J Lederer; Mauer Biscotti; Azka Javaid; Nina M Patel; Daniel Brodie; Matthew Bacchetta; Matthew R Baldwin Journal: Chest Date: 2018-01-17 Impact factor: 9.410
Authors: Sujal R Desai; Srihari Veeraraghavan; David M Hansell; Ageliki Nikolakopolou; Nicole S L Goh; Andrew G Nicholson; Thomas V Colby; Christopher P Denton; Carol M Black; Roland M du Bois; Athol U Wells Journal: Radiology Date: 2004-08 Impact factor: 11.105
Authors: Arik Bernard Schulze; Georg Evers; Andreas Kümmel; Felix Rosenow; Jan Sackarnd; Jan Philipp Hering; Christoph Schülke; Jonas Andreas Engelbertz; Dennis Görlich; Peter J Barth; Georg Lenz; Heidemarie Becker; Michael Mohr; Lars Henning Schmidt Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2019-05-01 Impact factor: 0.670
Authors: M Yates; R A Watts; I M Bajema; M C Cid; B Crestani; T Hauser; B Hellmich; J U Holle; M Laudien; M A Little; R A Luqmani; A Mahr; P A Merkel; J Mills; J Mooney; M Segelmark; V Tesar; K Westman; A Vaglio; N Yalçındağ; D R Jayne; C Mukhtyar Journal: Ann Rheum Dis Date: 2016-06-23 Impact factor: 27.973